# Gold Standard CCB — Scenario 5: Conflicting Data

**Patient:** PT-011, George Abrams, 61M  
**Alert:** BP 164/101 — URGENT  
**Scenario:** Patient claims full medication adherence; objective data (sub-therapeutic drug levels, inconsistent refill records, persistently elevated BP despite triple therapy) strongly suggests non-adherence. Patient is defensive when questioned.

---

## 1. Alert Summary
- **Triggered by:** Systolic BP 164.8 mmHg (+19.8 above threshold of 145), Diastolic 101.2 mmHg (+6.2 above threshold)
- **Urgency:** URGENT — BP persistently elevated despite three antihypertensive agents; pattern suggests treatment failure or non-adherence
- **Trend:** RPM shows persistent +25 mmHg offset throughout 30-day period — not acute, represents chronic uncontrolled state

## 2. Patient Snapshot
- **Active conditions:** Essential hypertension (I10), Type 2 diabetes mellitus (E11.9), Low back pain (M54.5)
- **Current medications:** Valsartan 160mg QD, Chlorthalidone 25mg QD, Amlodipine 10mg QD, Metformin 1000mg BID, Glipizide 10mg QD
- **Key history:** On triple antihypertensive therapy since 2019; HbA1c 7.8 despite claimed adherence; Glipizide levels sub-therapeutic on 2025-11-08 labs

## 3. Contextual Analysis
The central tension in this case is a direct conflict between self-reported and objective adherence data. The patient states he "never misses a dose" (anamnesis, visit note), yet: (1) Glipizide drug level is sub-therapeutic with estimated adherence <50% per refill records; (2) HbA1c of 7.8% is inconsistent with full adherence to Metformin + Glipizide; (3) BP of 158/96 (clinic) and 164/101 (RPM) is inconsistent with full adherence to Valsartan 160mg + Chlorthalidone 25mg + Amlodipine 10mg — a regimen that should achieve near-normal BP in most patients. The anamnesis documents defensive responses when adherence is broached. Additionally, the patient takes ibuprofen for back pain, which is an NSAIDs-antihypertensive interaction that can blunt BP control and worsen renal function. This is a clinically significant finding requiring attention independent of the adherence question.

## 4. Risk Assessment
- **Primary risk:** Sustained uncontrolled hypertension and suboptimal diabetes management — increased risk of cardiovascular events, nephropathy, retinopathy over time
- **Secondary risk:** NSAID use (ibuprofen) in a patient on antihypertensives and Metformin — risk of BP elevation, fluid retention, and renal impairment
- **Confidence:** 0.82 — Non-adherence is the most probable explanation; NSAID interaction is a confirmed contributing factor

## 5. Recommended Actions
1. **Non-confrontational adherence discussion** — Use motivational interviewing approach; validate difficulty of managing multiple medications; introduce pill organizer or blister packs. Evidence: anamnesis (DEFENSIVE_RESPONSE flag), EHR visit note (non-confrontational approach documented)
2. **Address ibuprofen use explicitly** — Patient is taking ibuprofen for back pain; NSAIDs antagonize antihypertensives and increase renal risk. Recommend switching to acetaminophen or consider naproxen discussion with caveats. Evidence: anamnesis (ibuprofen mentioned), EHR (current renal function Cr 1.0, still within normal range)
3. **Pharmacy refill audit** — Request 6-month refill history for all five medications to objectively quantify adherence patterns. Evidence: lab note (refill records for Glipizide showed <50% adherence)
4. **Repeat BMP and HbA1c in 4 weeks** — After addressing adherence and removing ibuprofen, reassess renal function and glycemic control. Evidence: EHR labs (BMP 2025-11-08, HbA1c 7.8%)
5. **Consider simplifying regimen** — Five medications is a high burden; assess if combination pills (e.g., Valsartan/Amlodipine) could reduce pill count and improve adherence. Evidence: polypharmacy (5 medications)

## 6. Uncertainties and Gaps
- **CONFLICTING_INFO:** Patient self-report contradicts objective drug levels and refill records — adherence status remains uncertain despite strong objective signals
- **MISSING_DATA:** Frequency and dose of ibuprofen use not quantified in anamnesis
- **LOW_CONFIDENCE:** Cannot determine whether uncontrolled BP is primarily due to non-adherence vs. true treatment resistance vs. NSAID effect vs. combination

## 7. Immediate Review Required
**No** — Chronic pattern; no acute emergency. Priority: scheduled visit with adherence conversation and ibuprofen cessation counseling within 1-2 weeks.
